Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study

被引:41
作者
Gadalla, S. M. [1 ,2 ]
Amr, S. [2 ]
Langenberg, P. [2 ]
Baumgarten, M. [2 ]
Davidson, W. F. [3 ]
Schairer, C. [1 ]
Engels, E. A. [1 ]
Pfeiffer, R. M. [1 ]
Goedert, J. J. [1 ]
机构
[1] Natl Canc Inst, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Univ Maryland, Dept Epidemiol & Prevent Med, Sch Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA
关键词
rheumatic diseases; autoimmune diseases; breast cancer; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRIMARY SJOGRENS-SYNDROME; LUPUS-ERYTHEMATOSUS; COHORT; MALIGNANCY; CYTOKINES; TRAIL; CELLS; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.1038/sj.bjc.6604906
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Systemic autoimmune rheumatic diseases (SARDs) are chronic inflammatory and immuno-modulatory conditions that have been suggested to affect cancer risk. Using the Surveillance, Epidemiology and End Results-Medicare-linked database, women aged 67-99 years and diagnosed with incident breast cancer in 1993-2002 (n = 84 778) were compared with an equal number of age-matched cancer-free female controls. Diagnoses of SARDs, including rheumatoid arthritis (RA, n = 5238), systemic lupus erythematosus (SLE, n = 340), Sjogren's syndrome (n = 374), systemic sclerosis (n = 128), and dermatomyositis (n = 31), were determined from claim files for individuals from age 65 years to 1 year before selection. Associations of SARD diagnoses with breast cancer, overall and by oestrogen receptor (ER) expression, were assessed using odds ratio (OR) estimates from multivariable logistic regression models. The women diagnosed with RA were less likely to develop breast cancer (OR = 0.87, 95% confidence interval (CI) = 0.82-0.93). The risk reduction did not differ by tumour ER-status (OR = 0.83, 95% CI = 0.78-0.89 for ER-positive vs OR = 0.91, 95% CI = 0.81-1.04 for ER-negative, P for heterogeneity = 0.14). The breast cancer risk was not associated with any of the other SARDs, except for a risk reduction of ER-negative cases (OR = 0.49, 95% CI = 0.26-0.93) among women with SLE. These findings suggest that systemic inflammation may affect breast epithelial neoplasia.
引用
收藏
页码:817 / 821
页数:5
相关论文
共 36 条
[1]
Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis [J].
Anderson, Lesley A. ;
Pfeiffer, Ruth ;
Warren, Joan L. ;
Landgren, Ola ;
Gadalla, Shahinaz ;
Berndt, Sonja I. ;
Ricker, Winnie ;
Parsons, Ruth ;
Wheeler, William ;
Engels, Eric A. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (11) :3069-3075
[2]
RELATION BETWEEN ESTROGEN-RECEPTOR CONCENTRATION AND CLINICAL AND HISTOLOGICAL FACTORS - THEIR RELATIVE PROGNOSTIC IMPORTANCE AFTER RADICAL-MASTECTOMY FOR PRIMARY BREAST-CANCER [J].
ANDRY, G ;
SUCIU, S ;
PRATOLA, D ;
SYLVESTER, R ;
LECLERCQ, G ;
DACOSTA, PM ;
LEGROS, N ;
ANDRYTHOOFT, M ;
VERHEST, A ;
MATTHEIEM, W ;
HEUSON, JC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :319-329
[3]
[Anonymous], CANC FACTS FIG 2007
[4]
Cytokines in the rheumatic diseases [J].
Arend, WP ;
Gabay, C .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (01) :41-+
[5]
Bernatsky S, 2003, J RHEUMATOL, V30, P1505
[6]
An International Cohort Study of Cancer in Systemic Lupus Erythematosus [J].
Bernatsky, S ;
Boivin, JF ;
Joseph, L ;
Rajan, R ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Petri, M ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Isenberg, D ;
Rahman, A ;
Aranow, C ;
Dooley, MA ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
Alarcón, G ;
Senécal, JL ;
Zummer, M ;
Hanly, J ;
Ensworth, S ;
Pope, J ;
El-Gabalawy, H ;
McCarthy, T ;
Pierre, YS ;
Ramsey-Goldman, R ;
Clarke, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1481-1490
[7]
Björnådal L, 2002, SCAND J RHEUMATOL, V31, P66
[8]
Risk of malignancy in scleroderma - A population-based cohort study [J].
Chatterjee, S ;
Dombi, GW ;
Severson, RK ;
Mayes, MD .
ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2415-2424
[9]
Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer [J].
Chen, Wendy Y. ;
Colditz, Graham A. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (07) :415-423
[10]
Systemic lupus erythematosus and the risk of malignancy [J].
Cibere, J ;
Sibley, J ;
Haga, M .
LUPUS, 2001, 10 (06) :394-400